IRLAB Signs Phase III Regulatory US Consultants to Support Preparation for Mesdopetam’s end-of-Phase 2 Meeting with the US FDA

IRLAB Therapeutics IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company has secured top expertise in supporting the preparations for Phase III with mesdopetam.